Wiesbaden, Germany

Jürgen Boer

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Amgen Inc.. Active years: 2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jürgen Boer. Retrieved from https://idiyas.com/inventor/jurgen-boer

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 


Average Co-Inventor Count = 11.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2011

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jürgen Boer - Innovator in Dipeptidyl Peptidase-IV Inhibitors

Introduction

Jürgen Boer is a notable inventor based in Wiesbaden, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit dipeptidyl peptidase-IV (DPP-IV). His work is particularly relevant for the treatment of Type-2 diabetes.

Latest Patents

Jürgen Boer holds a patent for "Dipeptidyl peptidase-IV inhibitors." This invention relates to pyrrolidine and thiazolidine DPP-IV inhibitor compounds. The patent also outlines synthetic methods for preparing these compounds, methods for inhibiting DPP-IV using them, and pharmaceutical formulations that contain these compounds for treating DPP-IV mediated diseases.

Career Highlights

Throughout his career, Jürgen Boer has worked with prominent companies in the pharmaceutical industry. He has been associated with Amgen Inc. and Alantos Pharmaceuticals Holding, Inc., where he has contributed to various innovative projects.

Collaborations

Jürgen Boer has collaborated with notable professionals in his field, including Heiko Kroth and Tim Feuerstein. These collaborations have further enhanced his research and development efforts.

Conclusion

Jürgen Boer is a distinguished inventor whose work on DPP-IV inhibitors has the potential to impact the treatment of Type-2 diabetes significantly. His contributions to the pharmaceutical industry reflect his commitment to innovation and improving healthcare outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…